CTRI/2021/08/035359已完成2 期
A prospective, randomized, double blind, placebo controlled, parallel group study to evaluate the safety and efficacy of Dose for your Liver (Dietary Supplement) in patients with Non-alcoholic Fatty Liver Disease (NAFLD)
Eetho Brands Inc0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing and able to provide written informed consent prior to any study-related activities being performed.
- •2. Able and willing to comply with the protocol, including availability for all scheduled study visits.
- •3. Male and Female patients aged between 18 years to 70, both inclusive.
- •4. Patients diagnosed with fatty liver (grades 1-3) based on liver USG.
- •5. Women of child bearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing any two acceptable methods of contraception.
- •6. Female patients with negative urine pregnancy test (only for female who has not completed 1 year after menopause & have not gone through hysterectomy or bilateral tubal ligation).
排除标准
- •1. Hypersensitivity to contents of Dose for your Liver or related class of drugs or to any of the excipients of the formulation.
- •2. Fatty liver secondary to alcohol consumption.
- •3. History of regular alcohol consumption exceeding 14 drinks per week for female subjects or 21 drinks per week for male subjects (1 drink is equal to 5 ounce (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within the previous 6 months from screening.
- •4. Addicted Alcoholics and- or drug abusers.
- •5. History or presence of coronary, renal, pulmonary and thyroid disease.
- •6. AST and ALT more than 5 times ULN; Serum bilirubin more than ULN and Platelet Count less than 95,000 per microleter.
- •7. Patients using hypolipidemic medications as well as any drug known to affect hepatic function 4 weeks prior to randomization.
- •8. Difficulty in swallowing and retaining oral formulation.
- •9. Known HBsAg positive, Anti HCV and HIV positive, hereditary defects of iron, copper and alpha-1 antitrypsin deficient patients.
- •10. Hypothyroidism, obstructive sleep apnoea, total parenteral nutrition, short bowel syndrome, pancreatoduodenal resection which are secondary causes of NAFLD.
- •11. Patient has condition or is in a situation which, in the investigatorââ?¬•s opinion, may have put the patient at a significant risk, may have confounded study results, or may have interfered significantly with the patientââ?¬•s participation in the study.
- •12. Participation in any other clinical study within 30 days before the first dose of Investigational Product.
- •13. Pregnant or Lactating female patient.
研究者
相似试验
已完成
4 期
Clinical study of Oligocare Forte Plus versus placebo in sub-fertile males.CTRI/2020/12/029590Meyer Organics Pvt Ltd300
已完成
2 期
A clinical study of Curcuvail�® in in patients with Non-alcoholic Fatty Liver DiseaseCTRI/2021/01/030302K Patel Phyto Extractions Pvt Ltd30
Unknown
1 期
A Clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ZYKR1 in healthy volunteers.CTRI/2018/07/014927Cadila Healthcare Ltd
已完成
不适用
A Clinical study to evaluate the efficacy and safety of bilberries extract capsules (180mg) in the eye health of human adults.CTRI/2016/05/006976Vidya herbs30
已完成
不适用
Evaluation of effects of fenugreek extract on body fat mass.CTRI/2013/10/004050Indus Biotech Private Limited Pune24